NASDAQ$SLN
Silence Therapeutics Plc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
SLN Q2 2025 — £200K revenue, 5.00 EPS
These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially differen. Silence Therapeutics Plc reported Q2 2025 results. Diluted EPS came in at 5.00. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: £200K.
- Diluted EPS: 5.00.
- Operating income: £24K.
- Gross profit: £139.
Headline financials
Revenue & EPS history
Silence Therapeutics · Revenue · Quarterly
$224K
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2025
-2.2%
Avg return
Earnings day
-1.1%
Avg return
5 days after
+4.4%
Avg return
30 days after
35%
7 / 20 earnings
Positive
+11.3%
Q2 2023
Best reaction
-16.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.8% | -7.7% | -16.3% | |
| Q4 2025 | -6.0% | +4.2% | -0.7% | |
| Q3 2025 | +2.9% | +7.7% | +11.5% | |
| Q2 2025 | +0.2% | +5.1% | +7.0% | |
| Q1 2025 | -1.7% | +26.6% | +31.3% | |
| Q4 2024 | -1.0% | -6.1% | -27.9% | |
| Q3 2024 | -16.7% | -54.3% | -57.7% | |
| Q4 2023 | -8.0% | -7.3% | -14.4% | |
| Q3 2023 | +4.6% | +1.0% | +74.5% | |
| Q2 2023 | +11.3% | +14.2% | +62.6% | |
| Q1 2023 | -7.2% | +1.9% | +3.9% | |
| Q4 2022 | -6.9% | -6.6% | -35.8% | |
| Q3 2022 | +10.7% | +17.4% | +32.1% | |
| Q2 2022 | -2.3% | -3.6% | +22.1% | |
| Q1 2022 | -1.8% | -14.6% | -6.1% | |
| Q4 2021 | -0.8% | +6.7% | +0.6% | |
| Q2 2021 | -14.3% | -11.8% | -9.7% | |
| Q1 2021 | +0.2% | +13.2% | +9.6% | |
| Q4 2020 | +0.2% | +0.2% | +13.7% | |
| Q3 2020 | -2.5% | -9.0% | -13.3% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro